ESMO 2018

Interviews and expert commentary from ESMO 2018 — study authors and key opinion leaders discuss the findings and their clinical implications.

Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib
Audio Journal of Oncology

Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib

BARCELONA—Oral cabozantinib “significantly improved” overall survival (OS) and progression free survival (PFS) compared to placebo in patients with advanced hepatocellular carcinoma(HCC) w

15 October 2018
8 mins